Iterum Therapeutics plc (ITRM) investors to reap big returns again – Marketing Sentinel

Iterum Therapeutics plc (ITRM) investors to reap big returns again

Iterum Therapeutics plc (NASDAQ:ITRM) has a beta value of 0 and has seen 3,243,244 shares traded in the last trading session. The company, currently valued at $220.34 Million, closed the last trade at $1.23 per share which meant it gained $0.04 on the day or 3.36% during that session. The ITRM stock price is -389.43% off its 52-week high price of $6.02 and 63.33% above the 52-week low of $0.451. If we look at the company’s 10-day average daily trading volume, we find that it stood at 8.47 Million shares traded. The 3-month trading volume is 26.75 Million shares.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

The consensus among analysts is that Iterum Therapeutics plc (ITRM) is a Hold stock at the moment, with a recommendation rating of 3. 1 analysts rate the stock as a Sell, while none rate it as Overweight. 1 out of 3 have rated it as a Hold, with 1 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$0.07.

Iterum Therapeutics plc (NASDAQ:ITRM) trade information

Sporting 3.36% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on Wednesday, Apr 28 when the ITRM stock price touched $1.27 or saw a rise of 3.15%. Year-to-date, Iterum Therapeutics plc shares have moved 24.37%, while the 5-day performance has seen it change 2.5%. Over the past 30 days, the shares of Iterum Therapeutics plc (NASDAQ:ITRM) have changed -13.38%. Short interest in the company has seen 4.54 Million shares shorted with days to cover at 0.17.

Wall Street analysts have a consensus price target for the stock at $2.25, which means that the shares’ value could jump 82.93% from current levels. The projected low price target is $2 while the price target rests at a high of $2.5. In that case, then, we find that the current price level is +103.25% off the targeted high while a plunge would see the stock lose 62.6% from current levels.

Iterum Therapeutics plc (ITRM) estimates and forecasts

Earnings growth for 2021 is a modest +69.5%.

Iterum Therapeutics plc (NASDAQ:ITRM)’s Major holders

Insiders own 0.6% of the company shares, while shares held by institutions stand at 9.01% with a share float percentage of 9.06%. Investors are also buoyed by the number of investors in a company, with Iterum Therapeutics plc having a total of 33 institutions that hold shares in the company. The top two institutional holders are Canaan Partners X LLC with over 1.73 Million shares worth more than $1.71 Million. As of December 30, 2020, Canaan Partners X LLC held 0.97% of shares outstanding.

The other major institutional holder is Frazier Management LLC, with the holding of over 1.54 Million shares as of December 30, 2020. The firm’s total holdings are worth over $1.52 Million and represent 0.86% of shares outstanding.

A Backdoor Way To Profit From Today’s Crypto Bull Market

Even if you’re not actively in crypto, you deserve to know what’s actually going on...

Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.

Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.

Sponsored


Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Leave a Comment

Your email address will not be published. Required fields are marked *

On Key

Related Posts

Get The Best Stocks To Trade Every Day!

Join now to get the Newsheater.com pre-market morning brief 100% free

We do not sell or share your information with anyone.

Get Best Morning Financial Newsletter... 100% Free

Best stocks ideas

Analysts’ Upgrades & Downgrades

Important Earnings

Insider Watchlist

We do not sell or share your information with anyone.